 Connection
David Ivy to United States
This is a "connection" page, showing publications David Ivy has written about United States.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.134 |
|
|
|
-
Jone PN, Ivy DD, Hauck A, Karamlou T, Truong U, Coleman RD, Sandoval JP, Del Cerro Mar?n MJ, Eghtesady P, Tillman K, Krishnan US. Pulmonary Hypertension in Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circ Heart Fail. 2023 07; 16(7):e00080.
Score: 0.018
-
Hopper RK, Ivy DD, Yung D, Mullen MP, Hanna BD, Kirkpatrick E, Hirsch R, Austin ED, Fineman J, Solum D, Deng CQ, Feinstein JA. Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol. 2020 07; 76(1):94-100.
Score: 0.014
-
Simpson CE, Damico RL, Hassoun PM, Martin LJ, Yang J, Nies MK, Vaidya RD, Brandal S, Pauciulo MW, Austin ED, Ivy DD, Nichols WC, Everett AD. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension. Chest. 2020 06; 157(6):1606-1616.
Score: 0.014
-
Hall K, Ogawa M, Sakarovitch C, Hopper RK, Adamson GT, Hanna B, Ivy DD, Miller-Reed K, Yung D, McCarthy E, Siehr-Handler SL, Feinstein JA. Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. J Cardiovasc Pharmacol. 2019 06; 73(6):383-393.
Score: 0.013
-
Bush D, Galambos C, Ivy DD, Abman SH, Wolter-Warmerdam K, Hickey F. Clinical Characteristics and Risk Factors for Developing Pulmonary Hypertension in Children with Down Syndrome. J Pediatr. 2018 11; 202:212-219.e2.
Score: 0.013
-
Sable CA, Ivy DD, Beekman RH, Clayton-Jeter HD, Jenkins KJ, Mahle WT, Morrow WR, Murphy MD, Nelson RM, Rosenthal GL, Stockbridge N, Wessel DL. 2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. Circ Cardiovasc Qual Outcomes. 2017 07; 10(7).
Score: 0.012
-
Zijlstra WM, Elmasry O, Pepplinkhuizen S, Ivy DD, Bonnet D, Luijendijk P, L?vy M, Gavilan JL, Torrent-Vernetta A, Mendoza A, Del Cerro MJ, Moledina S, Berger RM. Pulmonary arterial hypertension in children after neonatal arterial switch operation. Heart. 2017 08; 103(16):1244-1249.
Score: 0.011
-
Zijlstra WMH, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft MTR, Miller-Reed K, Hillege HL, Ivy DD, Berger RMF. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol. 2014 May 27; 63(20):2159-2169.
Score: 0.009
-
Barst RJ, Ivy DD, Foreman AJ, McGoon MD, Rosenzweig EB. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol. 2014 Jan 01; 113(1):147-55.
Score: 0.009
-
Maxey DM, Ivy DD, Ogawa MT, Feinstein JA. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients. Pediatr Cardiol. 2013 Oct; 34(7):1628-36.
Score: 0.009
-
Hill KD, Lim DS, Everett AD, Ivy DD, Moore JD. Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. Catheter Cardiovasc Interv. 2010 Nov 15; 76(6):865-73.
Score: 0.007
-
Torielli F, Fashaw LM, Knudson O, Kinsella J, Ivy D, Valdes-Cruz L, Rosenberg A. Echocardiographic outcome of infants treated as newborns with inhaled nitric oxide for severe hypoxemic respiratory failure. J Pediatr. 2001 Mar; 138(3):349-54.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|